Literature DB >> 11683480

Prevalence of insomnia in the adult Norwegian population.

S Pallesen1, I H Nordhus, G H Nielsen, O E Havik, G Kvale, B H Johnsen, S Skjøtskift.   

Abstract

A representative adult sample (18 years and above) of the Norwegian population, comprising 2001 subjects, participated in telephone interviews, focusing on the one-month point prevalence of insomnia and use of prescribed hypnotics. Employment of DSM-IV inclusion criteria of insomnia yielded a prevalence rate of 11.7%. Logistic regression analysis performed on the different insomnia symptoms revealed that somatic and psychiatric health were the strongest predictors of insomnia, whereas gender, age, and socioeconomic status showed a more inconsistent relationship. Use of prescribed hypnotic drugs was reported by 6.9% and was related to being female, elderly, and having somatic and emotional problems. Sleep onset problems and daytime impairment were more common during winter compared to summer. Use of hypnotics was more common in the southern (rather than the northern) regions of Norway. For sleep onset problems a Season x Region interaction was found, indicating that the prevalence of sleep onset problems increased in southern Norway from summer to winter, while the opposite pattern was found in the northern regions. The importance of clinically adequate criteria and seasonal variation in the evaluation of insomnia is briefly discussed.

Entities:  

Mesh:

Year:  2001        PMID: 11683480

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  42 in total

1.  Patterns of psychotropic medicine use and related diseases across educational groups: national cross-sectional survey.

Authors:  Merete W Nielsen; Ebba Holme Hansen; Niels Kristian Rasmussen
Journal:  Eur J Clin Pharmacol       Date:  2004-03-16       Impact factor: 2.953

2.  Prevalence and correlates of insomnia in a polish sample of alcohol-dependent patients.

Authors:  Nataliya Zhabenko; Marcin Wojnar; Kirk J Brower
Journal:  Alcohol Clin Exp Res       Date:  2012-04-04       Impact factor: 3.455

3.  Work factors as predictors of poor sleep in nurses' aides.

Authors:  Willy Eriksen; Bjørn Bjorvatn; Dag Bruusgaard; Stein Knardahl
Journal:  Int Arch Occup Environ Health       Date:  2007-06-29       Impact factor: 3.015

4.  Short sleep duration across income, education, and race/ethnic groups: population prevalence and growing disparities during 34 years of follow-up.

Authors:  Katherine A Stamatakis; George A Kaplan; Robert E Roberts
Journal:  Ann Epidemiol       Date:  2007-09-14       Impact factor: 3.797

5.  Effects of season on sleep and skin temperature in the elderly.

Authors:  Kazue Okamoto-Mizuno; Kazuyo Tsuzuki
Journal:  Int J Biometeorol       Date:  2009-12-30       Impact factor: 3.787

6.  Bidirectional associations of insomnia symptoms with somatic complaints and posttraumatic stress disorder in child and adolescent earthquake survivors: a longitudinal study.

Authors:  Ye Zhang; Jun Zhang; Rong Ren; Xiangdong Tang
Journal:  Sleep Breath       Date:  2019-11-08       Impact factor: 2.816

Review 7.  Residual effects of hypnotics: epidemiology and clinical implications.

Authors:  Annemiek Vermeeren
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  A warm footbath before bedtime and sleep in older Taiwanese with sleep disturbance.

Authors:  Wen-Chun Liao; Ming-Jang Chiu; Carol A Landis
Journal:  Res Nurs Health       Date:  2008-10       Impact factor: 2.228

9.  Sleep and sleep disorders in chronic users of zopiclone and drug-free insomniacs.

Authors:  Børge Sivertsen; Siri Omvik; Ståle Pallesen; Inger Hilde Nordhus; Bjørn Bjorvatn
Journal:  J Clin Sleep Med       Date:  2009-08-15       Impact factor: 4.062

10.  Prevalence, Correlates, and Predictors of Insomnia in the US Army prior to Deployment.

Authors:  Daniel J Taylor; Kristi E Pruiksma; Willie J Hale; Kevin Kelly; Douglas Maurer; Alan L Peterson; Jim Mintz; Brett T Litz; Douglas E Williamson
Journal:  Sleep       Date:  2016-10-01       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.